Evan Roberts Sells 6,268 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) insider Evan Roberts sold 6,268 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $102,544.48. Following the sale, the insider owned 826,554 shares of the company’s stock, valued at approximately $13,522,423.44. The trade was a 0.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Evan Roberts also recently made the following trade(s):

• On Thursday, January 15th, Evan Roberts sold 1,810 shares of Phreesia stock. The shares were sold at an average price of $16.38, for a total value of $29,647.80.
• On Thursday, January 8th, Evan Roberts sold 6,317 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total value of $107,452.17.

Phreesia Price Performance

Shares of PHR opened at $15.59 on Thursday. The firm has a market cap of $939.62 million, a PE ratio of -155.83 and a beta of 0.61. Phreesia, Inc. has a 52-week low of $15.40 and a 52-week high of $32.76. The business’s 50 day moving average price is $17.94 and its two-hundred day moving average price is $23.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.11. The company had revenue of $120.33 million during the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. Phreesia’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.25) EPS. On average, equities analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Recent operating results show improvement: Phreesia beat consensus EPS and reported revenue growth (quarterly revenue up ~12.7% year‑over‑year), supporting the business case for recovery at current multiples. MarketBeat PHR profile
• Positive Sentiment: Wall Street remains largely constructive — most analysts rate PHR a Buy and the consensus price target (~$30) is well above the current trading level, giving upside if growth continues. Analyst consensus
• Neutral Sentiment: Although insiders sold sizable blocks, each still retains a material stake after the trades (examples from filings: Evan Roberts ~826k, David Linetsky ~224k, Allison Hoffman ~170k, Balaji Gandhi ~150k, Amy Vanduyn ~159k), which may temper concerns about a loss of long‑term conviction. InsiderTrades summary
• Neutral Sentiment: Market context: volume is slightly above average and the stock is trading below its 50‑ and 200‑day moving averages and near its 52‑week low — conditions that can amplify moves but also offer a potential entry if fundamentals improve. Price performance
• Negative Sentiment: Coordinated insider selling is the primary near‑term driver of weakness: multiple senior executives sold on Jan 15–16 at ~ $16.36–$16.38 (combined ~29,511 shares). Visible, same‑period sales by several officers can prompt short‑term selling pressure as other holders react. Evan Roberts sale (example)
• Negative Sentiment: Insider sales may be interpreted as liquidity or diversification events rather than vote of no confidence, but absent clarifying disclosure (e.g., 10b5‑1 plans, option exercises) the market tends to treat clustered insider sales as a negative signal. SEC filings

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PHR. Moody National Bank Trust Division increased its position in shares of Phreesia by 63.8% during the 4th quarter. Moody National Bank Trust Division now owns 195,944 shares of the company’s stock valued at $3,315,000 after purchasing an additional 76,345 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Phreesia during the fourth quarter worth about $1,203,000. Diversified Trust Co. raised its position in Phreesia by 12.2% in the fourth quarter. Diversified Trust Co. now owns 51,422 shares of the company’s stock worth $870,000 after acquiring an additional 5,600 shares during the period. Tudor Investment Corp ET AL purchased a new position in Phreesia in the third quarter valued at about $4,173,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Phreesia during the 3rd quarter valued at approximately $183,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on PHR. Citigroup lowered their price objective on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Needham & Company LLC reissued a “buy” rating and set a $35.00 price objective on shares of Phreesia in a report on Monday, December 8th. Truist Financial set a $24.00 price objective on Phreesia in a research note on Thursday, January 8th. Barclays cut their target price on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 16th. Finally, Mizuho dropped their price objective on Phreesia from $36.00 to $28.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 10th. Seventeen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.